UNITED STATES OF AMERICA
In the Matter of Summit Technology, Inc., a Corporation, and DOCKET NO. 9286 The Commission having heretofore issued its complaint charging Respondent Summit Technology, Inc. ("Summit") with violation of Section 5 of the Federal Trade Commission Act, as amended, and Summit having been served with a copy of that complaint, together with a notice of contemplated relief; and Summit, its attorney, and counsel for the Commission having thereafter executed an agreement containing a consent order, an admission by Summit of all the jurisdictional facts set forth in the complaint, a statement that the signing of said agreement is for settlement purposes only and does not constitute an admission by Summit that the law has been violated as alleged in such complaint, or that the facts as alleged in such complaint, other than jurisdictional facts, are true and waivers and other provisions as required by the Commission's Rules; and The Secretary of the Commission having thereafter withdrawn this matter from adjudication in accordance with § 3.25(c) of its Rules; and The Commission having considered the matter and having thereupon accepted the executed consent agreement and placed such agreement on the public record for a period of sixty (60) days, and having duly considered the comment filed thereafter by interested persons pursuant to § 3.25 of its Rules, now in further conformity with the procedure prescribed in § 3.25 of its Rules, the Commission hereby makes the following jurisdictional findings and enters the following order: 1. Respondent is a corporation organized, existing, and doing business under and by virtue of the laws of Massachusetts with its office and principal place of business located at 21 Hickory Drive, Waltham, Massachusetts 02154. 2. The Federal Trade Commission has jurisdiction of the subject matter of this proceeding and of the respondent, and the proceeding is in the public interest. ORDER I IT IS ORDERED that, as used in this Order, the following definitions shall apply: A. The term "PPP" means Pillar Point Partners, the partnership formed between Summit Partner, Inc., and VISX Partner, Inc., on or about June 3, 1992. B. The term "Summit" or "Respondent" means Summit Technology, Inc., its directors, officers, employees, agents, representatives, successors, and assigns; its subsidiaries, divisions, groups, partnerships (including but not limited to Summit Partner, Inc.) and affiliates controlled by Summit Technology, Inc., and the respective directors, officers, employees, agents, representatives, successors, and assigns of each. C. The term "VISX" means VISX, Incorporated, its directors, officers, employees, agents, representatives, successors, and assigns; its subsidiaries, divisions, groups, partnerships (including but not limited to VISX Partner, Inc.) and affiliates controlled by VISX, Incorporated, and the respective directors, officers, employees, agents, representatives, successors, and assigns of each. D. The term "Commission" means the Federal Trade Commission. E. The term "person" means any natural person, corporate entity, partnership, association, joint venture, government entity, or trust. F. The term "Formation Agreement" means the agreement established in the document entitled "Formation Agreement Dated June 3, 1992," which was made and entered into on or about the 3rd day of June 1992, among Summit Technology, Inc., a Massachusetts corporation; VISX, Inc., a Delaware corporation; Summit Partner, Inc., a Delaware corporation; and VISX Partner, Inc., a Delaware corporation. G. The term "General Partnership Agreement" means the agreement established in the document entitled "General Partnership Agreement of Pillar Point Partners Dated June 3, 1992," which was made and entered into on or about the 3rd day of June 1992, by and between Summit Partner, Inc., a Delaware corporation, and VISX Partner Inc., a Delaware corporation. H. The term "Per-Procedure Fee" means any payment for the use of any product, device, method, patent, intellectual property, or technology, which payment depends in any way on the amount of use of, including the number of procedures performed using, the product, device, method, patent, intellectual property, or technology. I. The term "PRK" means photorefractive keratectomy, an excimer laser-based form of eye surgery used to correct refraction disorders. J. The term "PRK equipment" means any laser or other device that could be used in connection with performing PRK. K. The term "PPP Patents" means all patents that have been contributed to PPP pursuant to Articles 2.3 and 2.4 of the Formation Agreement and Article 6.2 of the General Partnership Agreement, and all patents that have been contributed to PPP since June 3, 1992. The term "PPP Patents" includes but is not limited to all patents listed in Schedule A and Schedule B of this Order. L. The term "Settlement and Dissolution Agreement" means the June 4, 1998 Settlement and Dissolution Agreement between Summit Technology, Inc. and VISX, Incorporated. The Settlement and Dissolution Agreement is appended to this Order in redacted form as Appendix I. II IT IS FURTHER ORDERED that Respondent, directly or indirectly, or through any person or other device, in or in connection with activities in or affecting commerce, as "commerce" is defined in Section 4 of the Federal Trade Commission Act, cease and desist, except as provided in Paragraph III of this Order or in the Settlement and Dissolution Agreement, from entering into, adhering to, participating in, enforcing or maintaining any contract, agreement, understanding, joint venture, pool, partnership, cross-license or other combination with VISX: A. (1) To fix, construct, stabilize, standardize, raise, maintain, or otherwise affect or control any price, royalty or fee for, any aspect of any price, royalty or fee for, or the terms or conditions associated with, the purchase, license or use of any product, device, method, patent, intellectual property, or technology that uses or is used in conjunction with, or claims, covers, embodies or incorporates in whole or in part the use of, a laser to perform any medical procedure, including but not limited to ophthalmic surgery; or
B. (1) To restrict the right or ability of Respondent or VISX to sell or license any product, device, method, patent, intellectual property, or technology that uses or is used in conjunction with, or claims, covers, embodies or incorporates in whole or in part the use of, a laser to perform any medical procedure, including but not limited to ophthalmic surgery; or
PROVIDED, HOWEVER, that nothing in this Order shall prevent Respondent from entering into or maintaining any contract, agreement, understanding, joint venture, pool, partnership, cross-license or other combination with VISX with respect to patents other than PPP Patents, if Respondent notifies the Commission in writing at least forty-five (45) days prior to entering into, forming or participating in such contract, agreement, understanding, joint venture, pool, partnership, cross-license or other combination. Such notification shall include (1) a description of the patent or patents subject to or affected by the contract, agreement, understanding, joint venture, pool, partnership, cross-license or other combination, including a copy of each such patent, and (2) a copy of the document or documents that memorialize all of the terms and conditions of the contract, agreement, understanding, joint venture, pool, partnership, cross-license or other combination, unless such document or documents do not exist at the time of the notification, in which case Respondent shall include a summary of the terms and conditions. III IT IS FURTHER ORDERED that Respondent shall, no later than twenty (20) days from the date this Order becomes final, license to VISX the patents that Respondent contributed to, or agreed to contribute to, PPP, including but not limited to all patents listed in Schedule A of this Order, and any divisions, reissues, re-examinations, continuations, continuations in part, renewals, extensions and additions thereof. Such license(s) shall be royalty-free and non-exclusive as set forth in the Settlement and Dissolution Agreement. IV IT IS FURTHER ORDERED that Respondent shall take no action inconsistent with the dissolution of PPP or the disposition of the PPP Patents as set forth in the Settlement and Dissolution Agreement. Consistent with the Settlement and Dissolution Agreement, PPP may wind up its affairs, defend or settle litigation in which it is or becomes a defendant and complete the defense of any such litigation. V IT IS FURTHER ORDERED that: A. Within sixty (60) days after the date this Order becomes final, Respondent shall distribute by first-class mail a copy of this Order (not including Appendix I) and the Complaint to any person that requested a license to use any of the PPP Patents in the manufacture, assembly or sale of PRK equipment since June 3, 1992. B. (1) Respondent shall allow any person ("Customer") with which Respondent entered into any agreement that includes an obligation to pay a Per-Procedure Fee to license any of the PPP Patents ("Agreement Containing License") between June 3, 1992 and June 5, 1998, to stop using the laser system covered by the Agreement Containing License, without any penalty or continuing obligation to Respondent under the Agreement Containing License or any other agreement with Respondent, other than obligations already incurred for goods, assets or services previously provided by Respondent, including any installment purchase or lease payments under any existing agreement for the purchase or lease of a laser system sold or leased by Respondent.
VI IT IS FURTHER ORDERED that: A. For a period of ten (10) years after the date this Order becomes final, Respondent shall distribute by first-class mail a copy of this Order (not including Appendix I) and the Complaint in this matter to any person that requests a license of any of Respondent's PPP Patents. B. Respondent shall file within sixty (60) days after the date this Order becomes final, annually thereafter for ten (10) years on the anniversary of the date this Order became final, and at such other times as the Commission may require, a verified written report setting forth in detail the manner and form in which it has complied and is complying with the Order. C. Respondent shall notify the Commission at least thirty (30) days prior to any proposed change in its structure, such as dissolution, assignment, sale resulting in the emergence of a successor corporation, or the creation or dissolution of subsidiaries or any other change that may affect compliance obligations arising out of the Order. D. For a period of ten (10) years after the date this Order becomes final, Respondent shall notify the Commission in writing forty-five (45) days prior to forming or participating in the formation of, or joining or participating in, any exclusive patent licensing arrangements, patent pool arrangements, partnerships or joint ventures if the arrangement, partnership or joint venture (1) involves United States patents that relate to the use, manufacture, marketing or sale of PRK equipment; and (2) includes any person engaged in the research, development, marketing or sale of PRK equipment. Such notification shall include a copy of the document or documents that memorialize all of the terms and conditions of the licensing arrangements, patent pool arrangements, partnerships or joint ventures, unless such document or documents do not exist at the time of the notification, in which case Respondent shall include a summary of the terms and conditions. E. For the purpose of determining or securing compliance with this Order, Respondent shall permit any duly authorized representative of the Commission: (1) access, during office hours and in the presence of counsel, to all facilities and access to inspect and copy all books, ledgers, accounts, correspondence, memoranda, calendars, and other records and documents in the possession or under the control of Respondent relating to any matters contained in this Order; and (2) upon five business days' notice to Respondent, and without restraint or interference from it, to interview officers, directors, or employees of Respondent in the presence of counsel representing said officers, directors or employees. VII IT IS FURTHER ORDERED that this Order will terminate upon the expiration of the last to expire of the PPP Patents. By the Commission. Donald S. Clark ISSUED: February 23, 1999 Schedule A Summit PPP Patents
Schedule B VISX PPP Patents
|